Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 20/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3777628 | 0.81 | HRH3 (0.62) | HRH3CYP2D6KCNH2 | |
| SCHEMBL3768860 | 0.80 | SIGMAR1 (0.46) | HRH3CYP2D6KCNH2 | |
| SCHEMBL3776585 | 0.78 | HRH3 (0.52) | HRH3CYP2D6KCNH2 | |
| SCHEMBL3780237 | 0.78 | HRH3 (0.45) | HRH3CYP2D6KCNH2 | |
| SCHEMBL3766350 | 0.78 | HRH3 (0.46) | HRH3CYP2D6KCNH2 | |
| SCHEMBL3777354 | 0.77 | HRH3 (0.58) | HRH3CYP2D6KCNH2 | |
| SCHEMBL3085867 | 0.77 | HRH3 (1.00) | HRH3CYP2D6 | |
| SCHEMBL3773401 | 0.75 | HRH3 (0.53) | HRH3CYP2D6 | |
| SCHEMBL4478245 | 0.75 | HRH3 (0.48) | HRH3CYP2D6KCNH2 | |
| SCHEMBL3077588 | 0.74 | HRH3 (0.95) | HRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | LIGAND PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | LIGAND PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | LIGAND PHARMACEUTICALS, INC. (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2009039431-A2 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | NEUROGEN CORPORATION (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039431-A2 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | NEUROGEN CORPORATION (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317679-A1 | SUBSTITUTED ARYL-FUSED SPIROCYCLIC AMINES | HRH3, HRH4, HRH2 | HRH3 1/4885CYP2D6 551/4885KCNH2 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.